undamentalytics Newsletter
Sign in

Vir Biotechnology, Inc. revenue

Vir Biotechnology, Inc.'s revenue was $68.6m in fiscal 2025, down 7.6% on the year before. Since fiscal 2017 ($2.7m) it has grown at a compound 49.8% a year. Over the last twelve months it was $303m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue3118761,0951,616867469303
Growth on the year before—+293.9%−24.2%+843.9%+>999%+47.5%−94.7%−13.9%−7.6%—
Gross profit——8761,0301,469837369—
Gross margin——100.0%100.0%94.0%90.9%96.8%98.9%100.0%—

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
License and Collaboration Revenue $63.1M 93.6% ▲ 2.9%
Other Revenue $3.4M 5.0% ▲ 44.7%
Grant $2M 3.0% ▼ 80.6%
Profit Sharing Amount Constrained $0 0.0% —
Profit Sharing Amount Previously Constrained Released $0 0.0% —
Profit Sharing Amount -$1.1M -1.7% ▼ 112.5%

From Vir Biotechnology, Inc.'s 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Vir Biotechnology, Inc. $303m 1495.9% -14.8%
Vericel Corp $306m 23.0% 19.8%
Adaptive Biotechnologies Corp $308m 50.1% 17.6%
Arvinas, Inc. $317m -15.0% 26.1%
Syndax Pharmaceuticals Inc $290m 159.7% 177.8%
Iovance Biotherapeutics, Inc. $325m 34.5% —

Compare with peers

Head to head: VCEL vs VIRADPT vs VIRARVN vs VIRSNDX vs VIR

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Vir Biotechnology, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Vir Biotechnology, Inc.